Pharmaceuticals (May 2024)

Impact of Cuminaldehyde and Indomethacin Co-Administration on Inflammatory Responses in MIA-Induced Osteoarthritis in Rats

  • Sebastião Vieira de Morais,
  • Gustavo Pereira Calado,
  • Rafael Cardoso Carvalho,
  • João Batista Santos Garcia,
  • Thyago Moreira de Queiroz,
  • Antonio José Cantanhede Filho,
  • Alberto Jorge Oliveira Lopes,
  • Maria do Socorro de Sousa Cartágenes,
  • Gerson Ricardo de Souza Domingues

DOI
https://doi.org/10.3390/ph17050630
Journal volume & issue
Vol. 17, no. 5
p. 630

Abstract

Read online

Osteoarthritis (OA) remains a chronic incurable condition, presenting substantial challenges in treatment. This study explores a novel strategy by investigating the concurrent use of cuminaldehyde, a natural compound, with indomethacin in animal models of MIA-induced OA. Our results demonstrate that the co-administration of cuminaldehyde and indomethacin does indeed produce a superior effect when compared to these compounds individually, significantly enhancing therapeutic outcomes. This effect is evidenced by a marked reduction in pro-inflammatory cytokines IL-6 and IFN-γ, alongside a significant increase in the anti-inflammatory cytokine IL-10, compared to treatments with each compound alone. Radiographic analyses further confirm the preservation of joint integrity and a reduction in osteoarthritic damage, highlighting the association’s efficacy in cartilage-reducing damage. These findings suggests that the association of cuminaldehyde and indomethacin not only slows OA progression but also offers enhanced cartilage-reducing damage and fosters the production of protective cytokines. This study underscores the potential benefits of integrating natural products with pharmaceuticals in OA management and stresses the importance of further research to fully understand the mechanisms underlying the observed potentiated effects.

Keywords